Cartesian: Maintaining 'Buy' On Descartes-08 MG Data Release And CAR-T Agreement

Cartesian Therapeutics maintains a 'Buy' rating, driven by advancing Descartes-08 cell therapy programs and imminent late-stage clinical catalysts. Topline results from the phase 3 AURORA study in AChR Ab+ Myasthenia Gravis are expected in Q1 2027, with a potential BLA filing in mid-2027. RNAC is expanding Descartes-08 into myositis indications and pursuing an in vivo CAR-T approach via a strategic WestGene licensing agreement, with initial data in H1 2027.

Seeking Alpha • 6 hours ago

Cartesian Therapeutics Announces New Employment Inducement Grants

FREDERICK, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to four new employees. On October 1, 2026, the Company issued to these employees options to purchase an aggregate of 121,900 shares of the Company's common stock with an exercise price of $7.22, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on October 1, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on October 1, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.

GlobeNewsWire • Oct 2, 2026

Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis

Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatment

GlobeNewsWire • Sep 29, 2026

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

FREDERICK, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September:

GlobeNewsWire • Sep 3, 2026

Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027

GlobeNewsWire • Aug 6, 2026

New Strong Sell Stocks for July 1st

CZR, RNAC and NSP have been added to the Zacks Rank #5 (Strong Sell) List on July 1, 2026.

Zacks Investment Research • Jul 1, 2026

Cartesian Therapeutics Announces New Employment Inducement Grant

FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an inducement award to one new employee.

GlobeNewsWire • Jun 12, 2026

New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) stock is up on Tuesday as the company is announcing a strategic licensing agreement with WestGene Biopharma.

Benzinga • Jun 9, 2026

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans to advance multiple Cartesian-owned, internally developed next-generation anti-BCMA CAR constructs and a BCMA-directed TCE as part of expanding mRNA payload portfolio Clinical trial expected to initiate in 2H 2026 using mRNA payload from Descartes-08 combined with WestGene's LNP platform in patients with MG; Clinical data expected in 1H 2027 FREDERICK, Md., June 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company” or “Cartesian”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced a strategic licensing agreement with WestGene Biopharma Co., Ltd.

GlobeNewsWire • Jun 9, 2026

Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027

Secured up to $150 million of non-dilutive financing from K2 HealthVentures; funding of $50 million from initial tranche extends cash runway into 2028

GlobeNewsWire • May 26, 2026